XENE - Xenon Pharmaceuticals Inc.
After hours:
| Previous close | 38.65 |
| Open | 38.74 |
| Bid | 35.75 x 800 |
| Ask | 38.96 x 1000 |
| Day's range | 38.09 - 39.08 |
| 52-week range | 26.25 - 43.57 |
| Volume | |
| Avg. volume | 382,711 |
| Market cap | 2.476B |
| Beta (5Y monthly) | 1.41 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Xenon Pharmaceuticals (XENE) Reports Q1 Loss, Lags Revenue Estimates
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -1.61% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Earnings Preview: Fortress Biotech (FBIO) Q1 Earnings Expected to Decline
Fortress Biotech (FBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Sutro Biopharma, Inc. (STRO) Soars 11.3%: Is Further Upside Left in the Stock?
Sutro Biopharma, Inc. (STRO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- Zacks
Xenon Pharmaceuticals (XENE) Expected to Beat Earnings Estimates: Should You Buy?
Xenon Pharmaceuticals (XENE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
Xenon Pharmaceuticals Full Year 2022 Earnings: Revenues Disappoint
Xenon Pharmaceuticals ( NASDAQ:XENE ) Full Year 2022 Results Key Financial Results Net loss: US$124.9m (loss widened by...
- Simply Wall St.
We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
- Zacks
Xenon Pharmaceuticals (XENE) Reports Q4 Loss, Lags Revenue Estimates
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 1.72% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.
Investors in Xenon Pharmaceuticals (NASDAQ:XENE) have made a fantastic return of 965% over the past five years
We think all investors should try to buy and hold high quality multi-year winners. While not every stock performs well...
- Simply Wall St.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Analysts Just Trimmed Their Revenue Forecasts By 10%
Market forces rained on the parade of Xenon Pharmaceuticals Inc. ( NASDAQ:XENE ) shareholders today, when the analysts...
- Zacks
Xenon Pharmaceuticals (XENE) Reports Q3 Loss, Misses Revenue Estimates
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -9.62% and 97.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.
Are Investors Undervaluing Xenon Pharmaceuticals Inc. (NASDAQ:XENE) By 32%?
How far off is Xenon Pharmaceuticals Inc. ( NASDAQ:XENE ) from its intrinsic value? Using the most recent financial...
- Simply Wall St.
What Does The Future Hold For Xenon Pharmaceuticals Inc. (NASDAQ:XENE)? These Analysts Have Been Cutting Their Estimates
One thing we could say about the analysts on Xenon Pharmaceuticals Inc. ( NASDAQ:XENE ) - they aren't optimistic...
- Zacks
Xenon Pharmaceuticals (XENE) Reports Q2 Loss, Misses Revenue Estimates
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -12.25% and 91.63%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.
What Type Of Shareholders Own The Most Number of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares?
Every investor in Xenon Pharmaceuticals Inc. ( NASDAQ:XENE ) should be aware of the most powerful shareholder groups...
- Simply Wall St.
Xenon Pharmaceuticals' (NASDAQ:XENE) investors will be pleased with their enviable 884% return over the last five years
We think all investors should try to buy and hold high quality multi-year winners. And we've seen some truly amazing...
